Scholars Central

Conference abstractPublished 8 Oct 2018

A pharmacological update of nephrotoxic drugs

Authors: Tasneem Sandozi

Dubai Medical College, UAE

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Tetracyclines & Glycylcyclines: Tetracycline, Oxytetracycline,Minocycline,Doxycycline,Tigecycline The catabolic effect of tetracyclines aggravates azotemia in patients with renal disease Fanconi syndrome: Outdated tetracyclines cause toxic effects on proximal renal tubules Amphotericin B: It is a broad spectrum antifungal drug having the broadest spectrum of activity Formulations: Four formulations available to make it suitable for intravenous administration as it is insoluble in water C-AMB: Amphotericin B is formulated with bile salt deoxychole Amphotericin B colloidal dispersion (ABCD),It contains equal amounts of amphotericin B and cholesteryl sulphate, Liposomal Amphotericin B (L-AMB),Amphotericin B is incorporated within unilamellar,liposomal vesicle formulation,Amphotericin B lipid (ABLC) It complex is a complex of two phospholipids Nephrotoxicity of AMP-B formulations Serum creatinine doubles by 57% during therapy Except C-AMB all three reduce risk of active kidney disease: Azotemia occurs in 80% of patients who receive C-AMB for deep mycosis ABLC has been observed to be more nephrotoxic than L-AMP-B in patients at high risk for nephrotoxicity Nephrotoxicity of AMP-B formulations: Serum creatinine doubles by 57% during therapy Lipid formulations decrease nephrotoxicity Except C-AMB all three reduce risk of active kidney disease Azotemia occurs in 80% of patients who receive C-AMB for deep mycosis ABLC has been observed to be more nephrotoxic than L-AMP-B in patients at high risk for nephrotoxicity In adults with normal renal function prior to treatment permanent functional impairment is uncommon even though permanent histological changes occur during short courses of C-AMB: Renal tubular acidosis & renal wasting of potassium & magnesium may also be seen several weeks after therapy Supplemental potassium is required in 1/3rd of the patients on prolonged therapy

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Nephrology & Therapeutics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Nephrology & Therapeutics
  • SubjectNephrology & Urology
  • BylineArticles whose byline prints “Tasneem Sandozi”